(Q2)May 31, 2024 | (Q1)Feb 29, 2024 | (FY)Nov 30, 2023 | (Q4)Nov 30, 2023 | (Q3)Aug 31, 2023 | (Q2)May 31, 2023 | (Q1)Feb 28, 2023 | (FY)Nov 30, 2022 | (Q4)Nov 30, 2022 | (Q3)Aug 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -98.89%-12.95K | 84.86%-15.06K | 82.61%-84.94K | 110.83%37.26K | -42.73%-16.25K | 74.03%-6.51K | 7.81%-99.44K | 43.67%-488.47K | -5,373.93%-344.15K | 95.26%-11.39K |
Net income from continuing operations | -61.61%-89.38K | 38.49%-37.16K | 91.35%-188.37K | 99.04%-18.24K | 48.76%-54.41K | 36.05%-55.3K | 26.56%-60.41K | -127.83%-2.18M | -3,727.65%-1.9M | 83.31%-106.19K |
Asset impairment expenditure | ---- | ---- | -101.47%-23.88K | ---- | ---- | ---- | ---- | --1.63M | ---- | ---- |
Change In working capital | 56.64%76.43K | 156.63%22.1K | 101.00%127.32K | 218.03%79.39K | -59.75%38.16K | -20.54%48.79K | -52.40%-39.02K | 120.25%63.34K | -242.12%-67.26K | 1,140.28%94.8K |
-Change in receivables | 87.04%60.42K | 22.87%19.5K | 248.77%28.19K | 356.16%29.86K | -1,767.48%-49.84K | 1,725.67%32.3K | 701.71%15.87K | 8.98%-18.95K | 50.29%-11.66K | 35.11%-2.67K |
-Change in payables and accrued expense | -2.91%16.01K | 104.73%2.6K | 20.45%99.12K | 189.07%49.53K | -9.71%88K | -73.99%16.49K | -139.00%-54.9K | 128.19%82.29K | -178.56%-55.61K | 2,049.40%97.47K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -98.89%-12.95K | 84.86%-15.06K | 82.61%-84.94K | 110.83%37.26K | -42.73%-16.25K | 74.03%-6.51K | 7.81%-99.44K | 43.67%-488.47K | -5,373.93%-344.15K | 95.26%-11.39K |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -122K | 0 | 31.25%-55K | 50.00%-25K | 0 | 0 | -50.00%-30K | 88.11%-80K | -50K | 96.67%-10K |
Net PPE purchase and sale | --0 | --0 | 31.25%-55K | ---- | ---- | --0 | -50.00%-30K | 88.11%-80K | ---- | ---- |
Net other investing changes | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | ---122K | --0 | 31.25%-55K | 58.33%-25K | --0 | --0 | -50.00%-30K | 88.11%-80K | ---60K | --0 |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 135K | 0 | -91.05%58.5K | 0 | -71.43%10K | 0 | -61.41%48.5K | -57.07%653.68K | 1,457.14%475K | -93.91%35K |
Net common stock issuance | --0 | --0 | -34.35%82.5K | --24K | --10K | --0 | -61.41%48.5K | -91.69%125.68K | --0 | --0 |
Net other financing activities | ---- | ---- | -104.55%-24K | ---- | ---- | ---- | ---- | --528K | --475K | --35K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | --135K | --0 | -91.05%58.5K | --0 | -71.43%10K | --0 | -61.41%48.5K | -57.07%653.68K | 1,457.14%475K | -93.91%35K |
Net cash flow | ||||||||||
Beginning cash position | -96.41%580 | -83.89%15.64K | 717.88%97.07K | -79.19%3.38K | 269.21%9.63K | 66.73%16.14K | 717.88%97.07K | -59.87%11.87K | -69.49%16.22K | -85.93%2.61K |
Current changes in cash | 100.80%52 | 81.40%-15.06K | -195.58%-81.44K | -84.83%12.26K | -145.94%-6.25K | 7.95%-6.51K | -3,597.35%-80.94K | 581.25%85.21K | 295.83%80.85K | -60.68%13.61K |
End cash Position | -93.44%632 | -96.41%580 | -83.89%15.64K | -83.89%15.64K | -79.19%3.38K | 269.21%9.63K | 66.73%16.14K | 717.88%97.07K | 717.88%97.07K | -69.49%16.22K |
Free cash from | -98.89%-12.95K | 88.37%-15.06K | 75.38%-139.94K | 95.82%-17.74K | 220.71%13.75K | -28.35%-6.51K | -1.23%-129.44K | 63.09%-568.47K | -6,646.40%-424.15K | 98.75%-11.39K |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.